Angiotech's Life After Drug Eluting Stents
Angiotech, best known for formulating the paclitaxel that goes on Boston Scientific's drug-eluting stent, has has signed two orthopedics deals; it's acquired NeuColl Inc., a private developer of collagen-based biomaterials for orthopedic applications and has also allied with Orthovita Inc., which will distribute Angiotech's hemostatic biomaterial in orthopedics markets. These, together with a string of other acquisitions in the past year, have diversified Angiotech into interventional cardiology, vascular surgery, anti-adhesion in gynecological surgery, and orthopedics--apparently unrelated fields. That represents a great deal of diversity for a mid-sized company with limited resources, but all of the areas share a common theme. Beyond the drug-eluting stent, Angiotech believes that potentially hundreds of large markets exist where drugs can improve the performance of devices.
You may also be interested in...
While the greater efficacy of drug-eluting stents (DES) compared to bare-metal stents is widely accepted, over the past year, data has continued to build showing that first-generation DES also have a higher late-stage in-stent thrombosis risk, a complication that can cause death 30% of the time, according to some estimates. The findings of these studies had some physicians at this year's World Congress of Cardiology calling for "an immediate halt to DES overuse." However, most conceded that additional randomized trials will be needed to fully understand the potential risks associated with these devices.
Discovery research is an ever more difficult investment to justify, so companies are placing greater emphasis on mining discoveries that have already been made but whose real value remains unexploited. Big Pharma, in part inhibited by habit and current infrastructure, has not moved aggressively in the new direction-but the jumpstart model now dominates small-company strategies and will increasingly translate into the rest of the industry.
Recent executive changes in the industry include the appointment of a new Chief Medical Officer at Caribou Biosciences and promotions at Exicure. Meanwhile, H-Cyte Inc., among other companies, has chosen new independent directors.